RT Book, Section
A1 Chihara, Dai
A1 Hagemeister, Fredrick B.
A1 Medeiros, L. Jeffrey
A1 Fanale, Michelle A.
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
SR Print(0)
ID 1126740891
T1 Hodgkin Lymphoma
T2 The MD Anderson Manual of Medical Oncology, 3e
YR 2016
FD 2016
PB McGraw-Hill Medical
PP New York, NY
SN 9780071847940
LK accessmedicine.mhmedical.com/content.aspx?aid=1126740891
RD 2024/04/20
AB Hodgkin  lymphoma  (HL)  was  recognized  in  the  first  half  of  the  nineteenth  century  by  Thomas  Hodgkin  and  Samuel  Wilks  (1).  HL  usually  arises  in  lymph  nodes,  preferentially  in  the  cervical  area,  and  the  majority  of  HLs  manifest  clinically  in  young  adults  in  their  third  and  fourth  decades  of  life.  The  incidence  of  HL  is  3.0  per  100,000  person-year  in  the  United  States;  it  is  higher  in  the  Western  countries  than  Asian  countries  (2,3).  Biological  and  clinical  studies  have  shown  that  HLs  are  comprised  of  two  disease  entities:  nodular  lymphocyte-predominant  HL  (NLPHL)  and  classical  HL  (cHL)  (1).  The  two  entities  differ  in  their  clinical  features  and  behavior.  Within  cHL,  four  subtypes  have  been  described:  nodular  sclerosis,  mixed  cellularity,  lymphocyte-rich,  and  lymphocyte-depleted.  These  four  subtypes  differ  in  their  clinical  features,  growth  pattern,  presence  of  fibrosis,  and  frequency  of  Epstein-Barr  virus  infection  but  share  the  immunophenotype  of  tumor  cells.